4 results
8-K
EX-99.1
RNXT
RenovoRx Inc
14 Nov 23
RenovoRx Reports Third Quarter 2023 Financial Results and Operational Highlights
12:00am
Position: Cash and cash equivalents as of September 30, 2023, were $3.2 million.
R&D Expenses: Research and development expenses were $1.6 million
8-K
EX-99.1
RNXT
RenovoRx Inc
17 Aug 23
RenovoRx Reports Second Quarter 2023 Financial Results and Operational Highlights
8:30am
proceeds of $5 million.
Second Quarter 2023 Financial Results:
Cash Position: Cash and cash equivalents as of June 30, 2023, were $6.0 million.
R&D Expenses
8-K
RNXT
RenovoRx Inc
27 Apr 23
Departure of Directors or Certain Officers
8:30am
governance committee of the Board of Directors.
Dr. Spiegel has over 30 years of extensive R&D and operational experience in biopharmaceuticals
- Prev
- 1
- Next